US2008213272A1PendingUtilityA1

Vegf-related protein

66
Assignee: LEE JAMESPriority: Sep 8, 1995Filed: Apr 3, 2008Published: Sep 4, 2008
Est. expirySep 8, 2015(expired)· nominal 20-yr term from priority
Inventors:James LeeWilliam I. Wood
A61P 5/14A61P 3/10A61P 35/00A61P 7/10A61P 7/00A61P 9/00A61P 43/00A61P 9/10A61P 9/14A61P 35/04A61P 27/06A61P 29/00A61P 27/02A61P 19/02C07K 14/71C07K 2319/00C07K 14/52A61P 13/12A61P 17/06A61P 17/02A61P 17/00A61K 38/00A61P 11/00C07K 16/22C07K 2319/30
66
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A human VEGF-related protein (VRP) has been identified and isolated that binds to, and stimulates the phosphorylation of, the receptor tyrosine kinase Flt4. The VRP is postulated to be a third member of the VEGF protein family. Also provided are antibodies that bind to VRP and neutralize a biological activity of VRP, compositions containing the VRP or antibody, methods of use, chimeric polypeptides, and a signal polypeptide for VRP.

Claims

exact text as granted — not AI-modified
1 . A monoclonal antibody that specifically binds to amino acid residues 1 to 157 or 21 to 157 of SEQ ID NO:3. 
     
     
         2 . The monoclonal antibody of  claim 1 , wherein the antibody neutralizes a biological activity of VRP. 
     
     
         3 . The monoclonal antibody of  claim 2 , wherein the biological activity of VRP is promoting neovascularization, vascular permeability, or vascular endothelial cell growth in a mammal. 
     
     
         4 . The monoclonal antibody of  claim 2 , comprising a humanized antibody. 
     
     
         5 . The monoclonal antibody of  claim 2 , comprising a chimeric antibody. 
     
     
         6 . A composition comprising a monoclonal antibody of  claim 2  with a pharmaceutically acceptable carrier.

Join the waitlist — get patent alerts

Track US2008213272A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.